Related Experiment Videos
[Implantable defibrillators--current status of guidelines. Recognized and possible indications--prerequisites]
1Abteilung für Innere Medizin mit Schwerpunkt Kardiologie und Pulmologie, Freien Universität Berlin.
Insights
Implantable cardioverter-defibrillators (ICDs) significantly reduce sudden cardiac death risk in high-risk patients. However, evidence is still needed to confirm if ICDs also improve overall survival rates in these individuals.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Context:
- Persistent ventricular tachycardia/fibrillation poses a significant risk of sudden cardiac death (SCD) within the first year post-resuscitation.
- Traditional anti-arrhythmic agents offer limited improvement in prognosis for these high-risk patients.
- Implantable cardioverter-defibrillators (ICDs) effectively terminate life-threatening arrhythmias, improving care for patients at high risk of SCD.
Purpose:
- To discuss the indication catalogue for implantable cardioverter-defibrillator (ICD) implantation based on a guideline paper.
- To evaluate the current evidence regarding the impact of ICDs on overall mortality in patients resuscitated from ventricular arrhythmias.
- To highlight the challenges in establishing long-term recommendations due to evolving technology and limited data.
Summary:
- ICDs reduce the annual risk of sudden cardiac death (SCD) to 1-2% in selected patient groups.
- The impact of ICDs on overall mortality, particularly in patients with preserved left ventricular function, requires further substantiation.
- Accurate patient selection for ICD therapy necessitates comprehensive cardiological diagnostics and specialized centers.
Impact:
- ICDs represent a significant advancement in managing patients at high risk of sudden cardiac death.
- Further research is crucial to definitively establish the benefits of ICDs on overall survival.
- The findings underscore the need for expert evaluation and management in specialized cardiological centers for optimal patient outcomes.
Abstract:
Ten to twenty percent of the patients, who were resuscitated as a result of a persistent ventricular tachycardia or ventricular fibrillation outside of an acute myocardial infarction, die of sudden cardiac death already in the first year after this event. Anti-arrhythmic agents also do not decisively improve this unfavorable prognosis. There is no doubt that the implantable cardioverter/defibrillator (ICD) safely and reliably terminates ventricular tachycardias and ventricular fibrillation and has thus led to an improvement in the care of these high risk patients. Studies have shown that the ICD reduces the risk of sudden cardiac death to 1-2% per year. However, whether the reduction of sudden cardiac death is also accompanied by a reduction in overall mortality has not yet been substantiated. It was, however, been assumed that especially patients with good left ventricular function, whose mortality risk is mainly sudden cardiac death, also profit from the overall prognosis of an ICD. The following presentation and discussion of the indication catalogue for the implantation of defibrillators is based on a guideline paper published by the study group "Interventional Electrophysiology" in the German Society for Cardiology. The statements clearly show how difficult it is to make long-term binding and valid recommendations due to insufficient scientific data and rapid technical development. Identifying patients who should be treated with an ICD requires complete noninvasive and invasive cardiological diagnostics and should ultimately be limited to cardiological centers which possess a large arsenal of diagnostic and therapeutic procedures.